Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13514515 | 0.89 | ENPP2 (0.50) | ENPP2CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL2312155 | 0.87 | ENPP2 (0.58) | ENPP2CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL3065782 | 0.86 | ENPP2 (0.48) | ENPP2CYP11B1CYP11B2SIRT2CYP3A4 | |
| SCHEMBL1978831 | 0.86 | ENPP2 (0.48) | ENPP2CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL17688341 | 0.86 | CYP2A6 (0.55) | ENPP2CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL4872173 | 0.85 | ENPP2 (0.56) | ENPP2CYP11B1CYP11B2RAB9ASIRT2 | |
| SCHEMBL14496825 | 0.85 | ENPP2 (0.47) | ENPP2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4172719 | 0.84 | ENPP2 (0.58) | ENPP2CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL4612796 | 0.82 | ENPP2 (0.46) | ENPP2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL18618168 | 0.82 | FYN (0.47) | ENPP2SIRT2HPGDSCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| CN-103038229-B | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-1828152-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1828152-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | Bristol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006062972-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0967207-B1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-09-11 | — | — | EP | disclosed |
| US-6034250-A | ANTIOXIDANTS | ADIR ET COMPAGNIE (FR) | 2000-03-07 | — | — | US | disclosed |
| EP-0967207-A1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | ENPP2 1332/4885CYP11B1 437/4885CYP11B2 503/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | ENPP2 3042/4885CYP11B1 72/4885CYP11B2 58/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | ENPP2 309/4885CYP11B1 402/4885CYP11B2 469/4885 |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | ENPP2 347/4885CYP11B1 2110/4885CYP11B2 2392/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | ENPP2 3042/4885CYP11B1 72/4885CYP11B2 58/4885 |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | ENPP2 1567/4885CYP11B1 772/4885CYP11B2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.